LynneAiBuiMD

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology

Founder & Chairman, Global Cancer Research Institute, Inc. Founder and Chairman GCRI Foundation, Inc. Ajdunct Clinical Professor Stanford Hospital & Clinics Co-Founder, President, and CEO Annam Pharma, Inc. President/CEO LBS Associates, LLC

Join to view full profile

Dr. Bui is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bui's full profile

Already have an account?

Office
9460 N Name Uno
Ste 230
Gilroy, CA 95020
Phone+1 408-384-9284

Fax+1 408-847-6196

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
David Geffen School of Medicine at UCLAClass of 1997

Certifications & Licensure

CA State Medical License 1998 - 2026

Clinical Trials

Study of XL999 in Patients With Previously Treated Ovarian Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 2
Study of XL999 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Study of XL999 in Patients With Multiple Myeloma Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of XL999 in Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2006 May 01
Terminated
Phase 2
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 1
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Start of enrollment: 2016 Dec 08
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

43 citations
Key considerations in the preclinical development of biosimilars.
Lynne A. Bui, Susan Hurst, Gregory L. Finch, Beverly Ingram, Ira Jacobs
Drug Discovery Today. 2015-05-01
20 citations
Developing Clinical Trials for Biosimilars
Lynne A. Bui, Carrie T. Taylor
Seminars in Oncology. 2014-02-01
35 citations
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Srdan Verstovsek, Constantine S. Tam, Martha Wadleigh, Lubomir Sokol, Catherine C. Smith
Leukemia Research. 2014-03-01

Press Mentions

Leaps by Bayer and Khloris Join Forces to Develop Induced Pluripotent Stem Cells (iPSCs) as Breakthrough Anti-Cancer VaccinesApril 2nd, 2019